Not Yet RecruitingNot Applicable

Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)

United States76 participantsStarted 2026-08-03

Plain-language summary

The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Self-reported mild to moderately-severe symptoms of depression (score 5-19 on PHQ-9).
✓. A diagnosis of stage 0-III breast, prostate, or colorectal cancer.
✓. Completion of primary cancer treatment within 2 years (excludes hormone therapy).
✓. An ability to provide informed consent.
✓. An ability to read and speak English.
✓. Access to a web-enabled device (phone, tablet, computer).

✕. Self-reported minimal and severe depressive symptoms (\<4 and \> 20 on PHQ-9).
✕. Self-reported suicidal ideation (\>1 on item 9 PHQ-9).
✕. Another psychological, medical, or other condition/issue determined that necessitates priority treatment and/or that would interfere with participation (e.g., schizophrenia, borderline personality disorder)
✕. Current or recent substance abuse/dependence.
✕. Stage IV cancer diagnosis.
✕. A cancer recurrence actively requiring treatment.
✕. Self-reported active mindfulness practice.
✕. Prior participation in a formal mindfulness program (e.g., MBCT, Mindfulness-Based Stress Reduction Program, Mindfulness-Based Cancer Recovery

Feasibility as assessed by listening rate

Timeframe: 12 weeks

Feasibility as assessed by sample retention rate

Timeframe: 12 weeks

Acceptability rate as assessed by satisfaction rating of daily audio content

Timeframe: 12 weeks

Acceptability rate as assessed by Client Satisfaction Questionnaire (CSQ-8) post-MINDSET

Timeframe: 12 weeks

NCT IDNCT06811454

SponsorCase Comprehensive Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-03-31

Narissa McCarty, MS

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Self-reported mild to moderately-severe symptoms of depression (score 5-19 on PHQ-9).
✓. A diagnosis of stage 0-III breast, prostate, or colorectal cancer.
✓. Completion of primary cancer treatment within 2 years (excludes hormone therapy).
✓. An ability to provide informed consent.
✓. An ability to read and speak English.
✓. Access to a web-enabled device (phone, tablet, computer).

✕. Self-reported minimal and severe depressive symptoms (\<4 and \> 20 on PHQ-9).
✕. Self-reported suicidal ideation (\>1 on item 9 PHQ-9).
✕. Another psychological, medical, or other condition/issue determined that necessitates priority treatment and/or that would interfere with participation (e.g., schizophrenia, borderline personality disorder)
✕. Current or recent substance abuse/dependence.
✕. Stage IV cancer diagnosis.
✕. A cancer recurrence actively requiring treatment.
✕. Self-reported active mindfulness practice.
✕. Prior participation in a formal mindfulness program (e.g., MBCT, Mindfulness-Based Stress Reduction Program, Mindfulness-Based Cancer Recovery

What they're measuring

Feasibility as assessed by listening rate

Timeframe: 12 weeks

Feasibility as assessed by sample retention rate

Timeframe: 12 weeks

Acceptability rate as assessed by satisfaction rating of daily audio content

Timeframe: 12 weeks

Acceptability rate as assessed by Client Satisfaction Questionnaire (CSQ-8) post-MINDSET

Timeframe: 12 weeks